Table 2.
Baseline characteristics based on management approach.
| Initial observation | Combined modality treatment | RT alone | Systemic treatment | P | |||||
|---|---|---|---|---|---|---|---|---|---|
| (N = 137) | (N = 21) | (N = 108) | (N = 29) | ||||||
| Characteristic | No. | % | No. | % | No. | % | No. | % | |
| Age: Median (IQR) | 58 (49–67) | 63 (57–70) | 56 (47–66) | 60 (53–67) | 0.29 | ||||
| Sex | |||||||||
| Female | 79 | 58 | 13 | 62 | 52 | 48 | 12 | 41 | 0.22 |
| Male | 58 | 42 | 8 | 38 | 56 | 52 | 17 | 59 | |
| Stage | |||||||||
| I | 60 | 44 | 16 | 76 | 92 | 85 | 4 | 14 | <0.001 |
| II | 77 | 56 | 5 | 24 | 16 | 15 | 25 | 86 | |
| Grade | |||||||||
| 1–2 | 115 | 93 | 8 | 38 | 83 | 88 | 21 | 84 | <0.001 |
| 3 A | 8 | 7 | 13 | 62 | 11 | 12 | 4 | 16 | |
| Unknown | 14 | 0 | 14 | 4 | |||||
| FLIPI score | |||||||||
| Low | 94 | 85 | 14 | 88 | 84 | 93 | 17 | 74 | 0.06 |
| Intermediate-High | 16 | 15 | 2 | 13 | 6 | 7 | 6 | 26 | |
| Unknown | 27 | 5 | 18 | 6 | |||||
| LDH | |||||||||
| Elevated | 13 | 14 | 2 | 13 | 5 | 6 | 5 | 24 | 0.09 |
| Normal | 83 | 86 | 14 | 88 | 76 | 94 | 16 | 76 | |
| Unknown | 41 | 5 | 27 | 8 | |||||
| Hemoglobin | |||||||||
| Decreased | 10 | 8 | 0 | 0 | 2 | 2 | 3 | 13 | 0.07 |
| Normal | 112 | 92 | 17 | 100 | 94 | 98 | 21 | 88 | |
| Unknown | 15 | 4 | 12 | 5 | |||||
| Nodal areas | |||||||||
| >4 | 6 | 4 | 0 | 0 | 0 | 0 | 2 | 7 | 0.05 |
| ≤4 | 131 | 96 | 21 | 100 | 108 | 100 | 27 | 93 | |
| Bulky disease (>7 cm) | |||||||||
| Yes | 13 | 20 | 3 | 19 | 5 | 6 | 9 | 41 | <0.001 |
| No | 52 | 80 | 13 | 81 | 82 | 94 | 13 | 59 | |
| Unknown | 72 | 5 | 21 | 7 | |||||
| PET staged | |||||||||
| Yes | 90 | 66 | 18 | 86 | 76 | 70 | 22 | 76 | 0.26 |
| No | 47 | 34 | 3 | 14 | 32 | 30 | 7 | 24 | |
| SUVmax | |||||||||
| >12 | 5 | 8 | 1 | 9 | 1 | 2 | 6 | 32 | 0.01 |
| ≤12 | 57 | 92 | 10 | 91 | 43 | 98 | 13 | 68 | |
| Unknown | 75 | 10 | 64 | 10 | |||||
| Bone marrow negativity | |||||||||
| Yes | 87 | 64 | 19 | 90 | 91 | 84 | 23 | 79 | 0.001 |
| Unknown | 50 | 36 | 2 | 10 | 17 | 16 | 6 | 21 | |
| Rituximab maintenance | |||||||||
| Yes | — | 1 | 5 | 0 | 0 | 4 | 14 | — | |
| No | — | 20 | 95 | 108 | 100 | 25 | 86 | ||
RT radiation therapy, OBS observation, CMT combined modality treatment, IQR interquartile range, FLIPI Follicular Lymphoma International Prognostic Index, LDH lactate dehydrogenase, PET positron emission tomography, SUV standard uptake value.